Nanotechnology for ocular therapeutics and tissue repair

Expert Review of Ophthalmology

Volumn 3, Issue 4, 2008, Pages 431-436

  Raju, Hemalatha B ^a   Goldberg, Jeffrey L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cornea; Gene therapy; Nanoparticle; Optic nerve; Retina; Stem cell; Tissue engineering

Indexed keywords

ALBUMIN; BASIC FIBROBLAST GROWTH FACTOR; CHITOSAN; CILIARY NEUROTROPHIC FACTOR; COLLAGEN; DEXTRAN; FIBRIN; GELATIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEIN; INDOMETACIN; LIPOSOME; MACROGOL; NANOCAPSULE; NANOPARTICLE; PLASMID DNA; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; RAPAMYCIN; RHODOPSIN; SILICONE; SMALL INTERFERING RNA; STARCH; TRIFLUOROACETIC ACID;

BIOCOMPATIBILITY; BIODEGRADABILITY; CELL TRANSPLANTATION; CLINICAL TRIAL; CORNEA DISEASE; CORNEA TRANSPLANTATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; ENCAPSULATION; EYE DISEASE; GENE THERAPY; GLAUCOMA; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KERATOPROSTHESIS; MATERIAL COATING; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PIGMENT EPITHELIUM; RABBIT; REGENERATIVE MEDICINE; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; RNA INTERFERENCE; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE REPAIR; TISSUE TRANSPLANTATION; UVEITIS; VITRECTOMY;

EID: 55149097203     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.4.431     Document Type: Review

References (35)

1. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEBJ. 19(3), 311-330 (2005).
2. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J. Pharm. Sci. 85(5), 530-536 (1996).
3. Yuan XB, Yuan YB, Jiang W et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int. J. Pharm. 349(1-2), 241-248 (2008).
4. Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol. Vis. 13, 1783-1792 (2007).
5. Sakai T, Kuno N, Takamatsu F et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats. Invest. Ophthalmol. Vis. Sci. 48(7), 3381-3387 (2007).
6. Tao W, Wen R, Goddard MB et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 43(10), 3292-3298 (2002).
7. Ward MS, Khoobehi A, Lavik EB, Langer R, Young MJ. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres. J. Pharm. Sci. 96(3), 558-568 (2007).
8. Sieving PA, Caruso RC, Tao W et al. Ciliary neurotrophic factor (CNTF) for human retinai degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl Acad. Sci. USA 103(10), 3896-3901 (2006).
9. Zhang G, Feng X, Wabner K et al. Intraocular nanoparticle drug delivery: a pilot study using an aerosol during pars plana vitrectomy. Invest. Ophthalmol. Vis. Sci. 48(11), 5243-5249 (2007).
10. Hashida N, Ohguro N, Yamazaki N et al. High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp. Eye Res. 86(1), 138-149 (2008).
11. Acland GM, Aguirre GD, Ray J et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28(1), 92-95 (2001).
12. Campochiaro PA, Nguyen QD, Shah SM et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum. Gene Ther. 17(2), 167-176 (2006).
13. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346-358 (2003).
14. Konstan MW, Davis PB, Wagener JS et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 15(12), 1255-1269 (2004).
15. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 1, e38 (2006).
16. Bejjani R, BenEzra D, Cohen H et al. Nanoparticles for gene delivery to retinal pigment epitheliai cells. Mol. Vis. 11(14), 124-132 (2005).
17. Jani PD, Singh N, Jenkins C et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest. Ophthalmol. Vis. Sci. 48(5), 2030-2036. (2007).
18. Bi A, Cui J, Ma YP et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 50(1), 23-33 (2006).
19. Prow T, Grebe R, Merges C et al. Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol. Vis. 12, 616-625 (2006).
20. Silva GA, Czeisler C, Niece KL et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303(5662), 1352-1355 (2004).
21. Diehl KA, Foley JD, Nealey PF, Murphy CJ. Nanoscale topography modulates corneal epithelial cell migration. J. Biomed. Mater. Res. A. 75(3), 603-611 (2005).
22. Ellis-Behnke RG, Liang YX, You SW et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc. Natl Acad. Sci. USA 103(13), 5054-5059 (2006).
23. Oweida AJ, Dunn EA, Foster PJ. Cellular imaging at 1.5 T: detecting cells in neuroinflammation using active labeling with superparamagnetic iron oxide. Mol. Imaging 3(2), 85-95 (2004).
24. Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J. Surg. Res. 95(2), 200-206 (2001).
25. Schutt W, Gruttner C, Hafeli U et al. Applications of magnetic targeting in diagnosis and therapy - possibilities and limitations: a mini-review. Hybridoma 16(1), 109-117 (1997).
26. Gallo JM, Hafeli U. Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 57(14), 3063-3065 (1997).
27. Bausch AR, Moller W, Sackmann E. Measurement of local viscoelasticity and forces in living cells by magnetic tweezers. Biophys. J. 76(1 Pt 1), 573-579 (1999).
28. Bausch AR, Ziemann F, Boulbitch AA, Jacobson K, Sackmann E. Local measurements of viscoelastic parameters of adherent cell surfaces by magnetic bead microrheometry. Biophys. J. 75(4), 2038-4209 (1998).
29. Sasaki T, Iwasaki N, Kohno K et al. Magnetic nanoparticles for improving cell invasion in tissue engineering. J. Biomed. Mater. Res. A. DOI 10.1002/jbm.a.31724 (2007) [Epub ahead of print].
30. Del Priore LV, Tezel TH, Kaplan HJ. Maculoplasty for age-related macular, degeneration: reengineering Bruch's membrane and the human macula. Prog. Retin. Eye Res. 25(6), 539-562 (2006).
31. MacLaren RE, Bird AC, Sathia PJ, Aylward GW. Long-term results of submacular surgery combined with macular translocation of the retinal pigment epithelium in neovascular age-related macular degeneration. Ophthalmology 112(12), 2081-2087 (2005).
32. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology 111(9), 1715-1724 (2004).
33. Ito A, Hibino E, Kobayashi C et al. Construction and delivery of tissue-engineered human retinal pigment epithelial cell sheets, using magnetite nanoparticles and magnetic force. Tissue Eng. 11(3-4), 489-496 (2005).
34. Fass JN, Odde DJ. Tensile force-dependent neurite elicitation via anti-β1 integrin antibody-coated magnetic beads. Biophys. J. 85(1), 623-636 (2003).
35. De Silva MN, Goldberg JL. Magnetic nanoparticle-based technology for repairing optic nerve. Presented at: ARVO Annual Meeting. Fort Lauderdale, FL, USA, 6-10 May 2007.